LAUNCH News
Genomics Launches Mystra AI Platform for Drug Discovery and Validation
Genomics, a Techbio company, has launched its Mystra AI platform, an agentic AI platform focused on supercharging drug target discovery and validation. The platform leverages the world's largest human
Chinese Supercomputer AI Platform Slashes Drug Screening Time
China has unveiled GalaxyVS, an AI platform powered by new-generation Tianhe supercomputers, dramatically reducing initial drug screening from months or years to tens of seconds. Developed by the Nati
Tempus Unveils Next-Gen Lens: Agentic AI for Oncology Drug Development
Tempus AI has launched the next-generation of its Lens platform, an agentic AI system designed to accelerate oncology drug development and research. This updated platform integrates multimodal data, A
Tempus Introduces 'Preview' to Accelerate Oncology Diagnostic Insights with AI
Tempus AI, Inc. has launched Tempus Preview, an AI-powered application designed to provide rapid, clinically significant insights in precision oncology. This new tool aims to close the critical time g
Microsoft Launches Copilot Health for AI-Powered Personal Health Management
Microsoft has launched a preview version of Copilot Health, an AI-powered platform designed to aggregate users' health records and wearable device data into a single, comprehensive profile. This tool,
Samsung Medical Center to Lead AI Surgical Robot Development with Government Funding
Samsung Medical Center has been selected to spearhead a new Ministry of Health and Welfare project, securing approximately 10 billion won (around $7.3 million USD) in government funding over five year
Chan Zuckerberg Biohub Unveils AI 'World Model' for Protein Design
The Chan Zuckerberg Biohub, a philanthropic venture by Mark Zuckerberg and Dr. Priscilla Chan, has launched an open-source AI 'world model' of protein biology. This model aims to accelerate drug disco
Ginkgo, Tangible Scientific, Inductive Bio Launch ADME-One™ for AI Drug Discovery
Ginkgo Bioworks, in partnership with Tangible Scientific and Inductive Bio, has launched ADME-One™, an integrated AI-powered platform designed to bring pharmacokinetic projection earlier into the drug
Perceptic Launches AI Operating System for Drug Development with $12M Seed Funding
Perceptic, an AI operating system for biopharma, has emerged from stealth with a $12M seed funding round led by Air Street Capital and Accel. Built by former Palantir AIP team members, the platform is
Kordata Dynamics Launches AI-Powered Precision Clinical Trials Platform with Pre-Seed Backing
Kordata Dynamics has emerged from stealth, launching an AI-powered precision clinical trials platform aimed at enhancing the speed, quality, and accessibility of clinical research. The company also se
Tempus Launches ArteraAI Prostate Test for Metastatic Patients
Tempus AI, a leader in artificial intelligence and precision medicine, has launched the ArteraAI Prostate Test (mHSPC) for clinical use. This CLIA-certified and CAP-accredited prognostic test, the fir
QIAGEN Launches QIA Agent for AI-Driven Scientific Guidance in Labs
QIAGEN has introduced QIA Agent, an AI-powered conversational tool designed to streamline how researchers access scientific information, product selection, and operational support within their Sample
IBM Research Unveils Open Biomedical AI Foundation Model MAMMAL
IBM Research has launched MAMMAL, a multimodal biomedical foundation model, making it openly available for research. Trained on approximately 2 billion biological samples, MAMMAL integrates proteins,
LLM Tool Boosts Phase III Trial Enrollment for Polycythemia Vera
Synapsis AI, a medically trained large language model, significantly reduced patient screening burdens and improved enrollment in a randomized, interventional Phase III clinical trial for polycythemia
Genesis AI Unveils GENE-26.5 Robotic System, Secures $105M Seed Funding
Genesis AI has launched its GENE-26.5 robotic manipulation system, featuring a human-scale dexterous hand designed for intricate tasks, including lab pipetting. The company also announced a significan
Insilico Medicine Unveils LabClaw for Autonomous AI Drug Discovery
Insilico Medicine, a generative AI-driven drug discovery company, announced the launch of LabClaw, an intelligent laboratory operating system. This system is designed to complement Insilico's fully au
Japan Opens Robotics Innovation Center, Deploys AI for Medical Diagnostics
The Institute of Science Tokyo has launched a new Robotics Innovation Center, housing Maholo humanoid robots developed with AIST and Yaskawa Electric, capable of performing up to 1,000 experiments 24/
Zuckerberg's Biohub Launches $500M Initiative for AI-Driven Cell Models
The Biohub, co-chaired by Mark Zuckerberg, has announced the Virtual Biology Initiative, committing $500 million to create massive biological datasets and develop AI models capable of simulating human
Motif Neurotech Gets FDA Greenlight for Depression BCI Trial
Motif Neurotech, a brain-computer interface (BCI) company focused on mental health, has received FDA approval for an Investigational Device Exemption (IDE) to begin the RESONATE Early Feasibility Stud
Lantern Pharma Expands predictBBB.ai into Global AI Drug Discovery Platform
Lantern Pharma Inc. has transformed its predictBBB.ai platform into a Large Quantitative Model (LQM), a real-time quantitative intelligence engine accessible globally via a single browser interface. T
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in UAE
Insilico Medicine, an AI-driven drug discovery company, has nominated ISM0387 as its first preclinical candidate discovered entirely in the UAE. The MTA-cooperative PRMT5 inhibitor for glioblastoma wa
OpenAI Launches GPT-Rosalind to Accelerate Drug Discovery
OpenAI has introduced 'GPT-Rosalind,' its first AI model tailored for accelerating early-stage research in biology, drug discovery, and translational medicine. Named after chemist Rosalind Franklin, t
OpenAI unveils GPT-Rosalind to accelerate AI drug discovery and biology research
OpenAI has launched "GPT-Rosalind," its first AI model designed to speed up early-stage research in biology, drug discovery, and translational medicine. This new reasoning model aims to address ineffi
AWS Launches Amazon Bio Discovery to Speed AI Drug Development
Amazon Web Services has introduced Amazon Bio Discovery, an AI-powered application designed to accelerate drug development. The platform provides scientists with direct access to specialized biologica
OpenAI Launches GPT-Rosalind AI Model for Drug Discovery and Life Sciences Research
OpenAI has unveiled GPT-Rosalind, a new domain-specific AI model designed to accelerate drug discovery and translational medicine. This model is tailored for complex biological research workflows, aim
Amazon Launches AI-Driven Bio Discovery Platform on AWS
Amazon Web Services (AWS) has launched its new AI-driven platform, Amazon Bio Discovery, to accelerate early-stage drug discovery for pharmaceutical and biotechnology industries. The platform integrat
OpenAI Unveils GPT-Rosalind AI Model for Accelerated Drug Discovery
OpenAI has launched GPT-Rosalind, a new AI model specifically designed for scientists in drug discovery, biology, and medical research. This specialized system integrates with over 50 daily scientific
OpenAI Debuts GPT-Rosalind AI Model for Accelerated Drug Discovery
OpenAI has launched GPT-Rosalind, an artificial intelligence model designed to significantly speed up drug discovery and scientific research, focusing on life sciences. This new model is optimized for
Caris Life Sciences Launches AI-Powered Molecular Insight for NSCLC Treatment
Caris Life Sciences has introduced a new AI-driven molecular insight designed to help identify whether adding chemotherapy benefits or harms non-small cell lung cancer (NSCLC) patients eligible for mo
Medtronic's AI Surgical System Gains FDA Clearance for Cranial & ENT
Medtronic has announced U.S. Food and Drug Administration (FDA) clearance for its AI-enabled Stealth AXiS surgical system, expanding its use to cranial and ear, nose, and throat (ENT) procedures. The
Basecamp Research Launches Trillion Gene Atlas for AI-Designed Therapeutics
Basecamp Research, in collaboration with Anthropic, Ultima Genomics, PacBio, and powered by NVIDIA AI, has launched the Trillion Gene Atlas. This initiative aims to expand known evolutionary genetic d
Persistent, NVIDIA Launch AI Generative Molecules & Virtual Screening Solution
Persistent Systems has partnered with NVIDIA to introduce a new AI-powered solution for generative molecules and virtual screening, aiming to accelerate early-stage drug discovery for healthcare and l
PerturbAI Launches from Stealth with World's Largest In Vivo CRISPR Atlas
PerturbAI, an AI-native therapeutics company, emerged from stealth on March 17, 2026, announcing the public release of the world's largest in vivo CRISPR atlas. This extensive 8 million-cell, brain-wi
Roche Scales NVIDIA AI Factories Globally to Accelerate Drug Discovery & Diagnostics
Roche is deploying over 3,500 NVIDIA Blackwell GPUs across its global operations, significantly expanding its AI infrastructure to accelerate drug discovery, diagnostic solutions, and manufacturing ef
Micro CRISPR: Revolutionizing Biotech with AI-Driven Speed
Micro CRISPR, a new biotech company spun out of Meril Life Sciences, is pioneering an AI-driven approach to drug discovery. The company aims to combine the rapid pace of technology with rigorous scien
Kala Bio to Deploy First Commercial AI Agent for Biotech R&D in 14 Days
Kala Bio, in collaboration with Younet.ai, announced it is ready to ship its first commercial AI agent from the rebranded Researgency.ai platform within approximately 14 days. This strategic move tran
Kala Bio Launches Researgency.ai, Pivots to AI for Biotech Operations
Kala Bio (NASDAQ: KALA) has launched its enterprise AI platform, Researgency.ai, marking a strategic shift to become a dual-engine company combining its drug pipeline with a scalable AI product. The c
LabVantage Solutions Introduces AI-Driven CORTEX Platform
LabVantage Solutions, a global provider of laboratory informatics, has launched LabVantage CORTEX, a new AI, analytics, and automation platform. This cloud-native platform integrates advanced AI and s
LabVantage Launches CORTEX for AI-Driven Lab Operations
LabVantage Solutions has introduced LabVantage CORTEX, an advancement to its LIMS platform that integrates agentic AI and cloud-native automation to enhance laboratory efficiency, reduce errors, and p
Eli Lilly Launches World's Most Powerful AI Factory for Drug Discovery
Eli Lilly has launched "LillyPod," an AI factory powered by over 1,000 NVIDIA Blackwell Ultra GPUs, making it the most powerful AI supercomputer owned by a pharmaceutical company. This initiative aims
NVIDIA Corporation Unveils Large Language Model for Pharmaceutical & Drug Development Biology
NVIDIA Corporation has entered the foundation models for biology arena with NVIDIA BioNeMo, a platform that gpu-accelerated foundation models and microservices for drug discovery and protein engineering. The move positions the company in a market projected to reach $2.1 billion by 2028, where biolog...
Isomorphic Labs Ltd. Brings AI Virtual Screening to Pharmaceutical & Drug Development Discovery Teams
For pharmaceutical & drug development operators looking to modernize their ai drug discovery capabilities, Isomorphic Labs Ltd. is pitching a compelling proposition. Isomorphic Labs reimagining drug discovery with ai to design medicines faster than ever before, addressing a market where 65% of top-2...
BenevolentAI Holdings Ltd. Unveils Next-Gen Target Identification Engine for Pharmaceutical & Drug Development
As the ai drug discovery market heats up — analysts project it will reach $4.9 billion by 2028 — BenevolentAI Holdings Ltd. has made its move. The company's platform, BenevolentAI, ai-powered drug discovery from target identification through to clinical candidate selection. BenevolentAI has built an...
Relay Therapeutics, Inc. Launches AI-Powered Drug Discovery Platform for Pharmaceutical & Drug Development
The ai drug discovery segment is undergoing rapid transformation as enterprises embrace a new reality: AI virtual screening is replacing high-throughput screening in lead identification. Relay Therapeutics, Inc. is positioning itself at the center of this shift with Relay Therapeutics, which harness...
Absci Corporation Rolls Out AI Structure Prediction for Biotechnology Startups Biologics
The generative biology segment is undergoing rapid transformation as enterprises embrace a new reality: generative AI is designing novel proteins with desired functional properties. Absci Corporation is positioning itself at the center of this shift with Absci Corporation, which generative ai drug c...
MIT Jameel Clinic / MIT CSAIL Deploys Generative AI for Novel Protein Design in Academic Research & Universities
For academic research & universities operators looking to modernize their protein structure & design capabilities, MIT Jameel Clinic / MIT CSAIL is pitching a compelling proposition. Boltz-1 open-source biomolecular structure prediction model matching alphafold 3 accuracy for free, addressing a mark...
OpenFold Consortium Rolls Out AI Structure Prediction for Academic Research & Universities Biologics
OpenFold Consortium has entered the protein structure & design arena with OpenFold, a platform that open-source, trainable reimplementation of alphafold 2 for research and model development. The move positions the company in a market projected to reach $2.8 billion by 2028, where AlphaFold has predi...
Inside Meta AI (Meta Platforms, Inc.)'s Foundation Model Powering Academic Research & Universities Discovery
The foundation models for biology segment is undergoing rapid transformation as enterprises embrace a new reality: foundation models are unifying genomics, proteomics, and chemistry into single architectures. Meta AI (Meta Platforms, Inc.) is positioning itself at the center of this shift with ESMFo...
Academic Research & Universities Teams Turn to Steinegger Lab / Söding Lab (Open Collaboration) for AI-Driven Protein Design
As the protein structure & design market heats up — analysts project it will reach $2.8 billion by 2028 — Steinegger Lab / Söding Lab (Open Collaboration) has made its move. The company's platform, ColabFold, alphafold2 made accessible in minutes using fast mmseqs2 sequence search. ColabFold is an o...
Biotechnology Startups Teams Turn to Chai Discovery, Inc. for AI-Driven Protein Design
As the protein structure & design market heats up — analysts project it will reach $2.8 billion by 2028 — Chai Discovery, Inc. has made its move. The company's platform, Chai-1, open-source molecular structure prediction model rivaling alphafold 3 for drug discovery. Chai Discovery developed Chai-1,...
GROMACS Development Team (Open Source) Unveils AI Molecular Simulation Engine for Academic Research & Universities
With physics-based simulations are used in 70% of drug design programs, the case for AI-powered computational chemistry has never been stronger. GROMACS Development Team (Open Source) is betting on this trend with GROMACS, a platform that high-performance open-source molecular dynamics engine for bi...
Profluent Bio, Inc. Launches Next-Gen Protein Engineering Platform for Biotechnology Startups
Profluent Bio, Inc. has entered the generative biology arena with Profluent, a platform that generative ai designing novel proteins and gene editors including the first ai-created crispr system. The move positions the company in a market projected to reach $2.8 billion by 2028, where AlphaFold has p...
Generate:Biomedicines, Inc. Deploys Generative AI for Novel Protein Design in Pharmaceutical & Drug Development
Generate:Biomedicines, Inc. has entered the generative biology arena with Generate:Biomedicines, a platform that generative ai platform designing de novo protein therapeutics entirely from computational first principles. The move positions the company in a market projected to reach $2.8 billion by 2...
Seqera Labs (Open Source) Releases Biological Foundation Model for Academic Research & Universities Research
As the bioinformatics platforms market heats up — analysts project it will reach $2.1 billion by 2028 — Seqera Labs (Open Source) has made its move. The company's platform, Nextflow, scalable, reproducible scientific workflow orchestration for data-intensive bioinformatics pipelines. Nextflow is an ...
Inside Moderna, Inc.'s Push to Democratize Pharmaceutical & Drug Development Synthetic Biology
Moderna, Inc. has entered the synthetic biology platforms arena with Moderna, a platform that mrna medicines platform developing vaccines, cancer immunotherapies, and rare disease therapeutics. The move positions the company in a market projected to reach $3.4 billion by 2028, where 500+ engineered ...
Pivot Bio, Inc. Launches AI-Guided Strain Engineering Platform for Agricultural & Food Science
Pivot Bio, Inc. has entered the synthetic biology platforms arena with Pivot Bio, a platform that microbial nitrogen products that feed crops from within the root zone, reducing synthetic fertilizer dependence. The move positions the company in a market projected to reach $3.4 billion by 2028, where...
Solugen Inc. Introduces DBTL Acceleration Engine for Biomanufacturing & Bioprocess
For biomanufacturing & bioprocess operators looking to modernize their synthetic biology platforms capabilities, Solugen Inc. is pitching a compelling proposition. Solugen chemienzymatic platform producing industrial chemicals from bio-based feedstocks at petrochemical scale and cost, addressing a m...
BioNTech SE Unveils Foundry-as-a-Service for Pharmaceutical & Drug Development Synthetic Biology
For pharmaceutical & drug development operators looking to modernize their synthetic biology platforms capabilities, BioNTech SE is pitching a compelling proposition. BioNTech mrna immunotherapy and vaccine platform developing individualized cancer medicines and infectious disease vaccines, addressi...
Inside Corteva Agriscience (NYSE: CTVA)'s Push to Democratize Agricultural & Food Science Synthetic Biology
With 500+ engineered organisms are in commercial pipelines, the case for AI-powered synthetic biology platforms has never been stronger. Corteva Agriscience (NYSE: CTVA) is betting on this trend with Corteva Agriscience, a platform that integrated crop science company combining seed genetics, crop p...
Bayer AG (Crop Science Division) Launches AI-Guided Strain Engineering Platform for Agricultural & Food Science
As the synthetic biology platforms market heats up — analysts project it will reach $3.4 billion by 2028 — Bayer AG (Crop Science Division) has made its move. The company's platform, Bayer Crop Science, integrated agricultural science combining digital farming intelligence, crop protection, and biol...
Inari Agriculture, Inc. Introduces DBTL Acceleration Engine for Agricultural & Food Science
Inari Agriculture, Inc. has entered the synthetic biology platforms arena with Inari Agriculture, a platform that gene editing and predictive design platform creating multiplexed trait improvements in seeds to feed a growing planet. The move positions the company in a market projected to reach $3.4 ...
LanzaTech Global, Inc. Unveils Foundry-as-a-Service for Biomanufacturing & Bioprocess Synthetic Biology
For biomanufacturing & bioprocess operators looking to modernize their synthetic biology platforms capabilities, LanzaTech Global, Inc. is pitching a compelling proposition. LanzaTech carbon capture and biorefinery platform converting waste industrial gases into sustainable fuels and chemicals, addr...
Inside Novonesis A/S's Push to Democratize Biomanufacturing & Bioprocess Synthetic Biology
Novonesis A/S has entered the synthetic biology platforms arena with Novonesis, a platform that the world's largest biosolutions company, engineering microorganisms and enzymes for every industry on earth. The move positions the company in a market projected to reach $3.4 billion by 2028, where 500+...
Arzeda Corporation Deploys Generative AI for Novel Protein Design in Biomanufacturing & Bioprocess
Arzeda Corporation has entered the generative biology arena with Arzeda, a platform that computational protein design platform engineering novel enzymes and proteins for industrial and therapeutic applications. The move positions the company in a market projected to reach $2.8 billion by 2028, where...
How Xaira Therapeutics, Inc. Is Accelerating Pharmaceutical & Drug Development Drug Discovery with Machine Learning
For pharmaceutical & drug development operators looking to modernize their ai drug discovery capabilities, Xaira Therapeutics, Inc. is pitching a compelling proposition. Xaira Therapeutics ai-native drug discovery company building generative biology models to design medicines from first principles, ...
Codexis, Inc. Launches AI-Guided Strain Engineering Platform for Biomanufacturing & Bioprocess
For biomanufacturing & bioprocess operators looking to modernize their synthetic biology platforms capabilities, Codexis, Inc. is pitching a compelling proposition. Codexis engineered enzyme technology platform powering sustainable pharmaceutical synthesis and industrial biotransformations, addressi...
Neuralink Corporation Deploys Brain-Computer Interface Technology Across Healthcare & Hospital Systems
As the brain-computer interfaces & neurotech market heats up — analysts project it will reach $1.4 billion by 2028 — Neuralink Corporation has made its move. The company's platform, Neuralink, implantable brain-computer interface restoring movement and communication for paralyzed patients. Neuralink...
Synchron, Inc. Unveils AI-Powered Neurostimulation Platform for Healthcare & Hospital Systems
With 200K+ patients are using FDA-cleared neurostimulation devices, the case for AI-powered brain-computer interfaces & neurotech has never been stronger. Synchron, Inc. is betting on this trend with Synchron, a platform that endovascular brain-computer interface enabling thought-controlled devices ...
How Blackrock Neurotech, Inc. Is Advancing Healthcare & Hospital Systems Neurotech with Adaptive AI
The brain-computer interfaces & neurotech segment is undergoing rapid transformation as enterprises embrace a new reality: closed-loop neural interfaces are enabling adaptive therapy protocols. Blackrock Neurotech, Inc. is positioning itself at the center of this shift with Blackrock Neurotech, whic...
Paradromics, Inc. Launches Closed-Loop Neural Interface for Healthcare & Hospital Systems
The brain-computer interfaces & neurotech segment is undergoing rapid transformation as enterprises embrace a new reality: closed-loop neural interfaces are enabling adaptive therapy protocols. Paradromics, Inc. is positioning itself at the center of this shift with Paradromics, which high-bandwidth...
Precision Neuroscience Corporation Unveils AI-Powered Neurostimulation Platform for Healthcare & Hospital Systems
Precision Neuroscience Corporation has entered the brain-computer interfaces & neurotech arena with Precision Neuroscience, a platform that minimally invasive layer 7 cortical interface enabling reversible, high-resolution brain-computer interfacing. The move positions the company in a market projec...
Emulate, Inc. Introduces DBTL Acceleration Engine for Pharmaceutical & Drug Development
As the organ-on-chip & organoids market heats up — analysts project it will reach $3.4 billion by 2028 — Emulate, Inc. has made its move. The company's platform, Emulate, human organ-on-chip technology delivering living tissue models for predictive drug testing. Emulate commercialized the organ-on-c...
MIMETAS B.V. Unveils Foundry-as-a-Service for Pharmaceutical & Drug Development Synthetic Biology
MIMETAS B.V. has entered the organ-on-chip & organoids arena with MIMETAS OrganoPlate, a platform that high-throughput 3d tissue models on organoplate enabling scalable organ-on-chip drug screening. The move positions the company in a market projected to reach $3.4 billion by 2028, where 500+ engine...
CN Bio Innovations Ltd. Introduces DBTL Acceleration Engine for Pharmaceutical & Drug Development
CN Bio Innovations Ltd. has entered the organ-on-chip & organoids arena with CN Bio PhysioMimix, a platform that scalable multi-organ-on-chip system for hepatotoxicity, dili prediction, and nash disease modeling. The move positions the company in a market projected to reach $3.4 billion by 2028, whe...
Hesperos, Inc. Introduces DBTL Acceleration Engine for Pharmaceutical & Drug Development
With 500+ engineered organisms are in commercial pipelines, the case for AI-powered organ-on-chip & organoids has never been stronger. Hesperos, Inc. is betting on this trend with Hesperos Human-on-a-Chip, a platform that serum-free multi-organ human-on-a-chip platform for systemic drug efficacy and...
Inside STEMCELL Technologies Inc.'s Push to Democratize Biotechnology Startups Synthetic Biology
For biotechnology startups operators looking to modernize their organ-on-chip & organoids capabilities, STEMCELL Technologies Inc. is pitching a compelling proposition. StemCell Technologies the world's leading provider of specialized cell culture reagents and tools for stem cell and organoid resear...
How Caporaso Lab / University of Northern Arizona (community-maintained) Is Transforming Academic Research & Universities Microbiome Research with AI
Caporaso Lab / University of Northern Arizona (community-maintained) has entered the microbiome analysis & therapeutics arena with QIIME 2, a platform that the leading open-source platform for reproducible microbiome bioinformatics analysis. The move positions the company in a market projected to re...
CosmosID, Inc. Launches AI Microbiome Analytics Platform for Diagnostic & Clinical Labs
For diagnostic & clinical labs operators looking to modernize their microbiome analysis & therapeutics capabilities, CosmosID, Inc. is pitching a compelling proposition. CosmosID ai-powered metagenomic sequencing analytics delivering strain-level microbiome profiling and insights, addressing a marke...
How Seres Therapeutics, Inc. Is Transforming Pharmaceutical & Drug Development Microbiome Research with AI
Seres Therapeutics, Inc. has entered the microbiome analysis & therapeutics arena with VOWST (Seres Therapeutics), a platform that first fda-approved oral microbiome therapeutic preventing recurrent c. difficile infection. The move positions the company in a market projected to reach $1.6 billion by...
Vedanta Biosciences, Inc. Launches AI Microbiome Analytics Platform for Pharmaceutical & Drug Development
With metagenomics has identified 150K+ novel gut species, the case for AI-powered microbiome analysis & therapeutics has never been stronger. Vedanta Biosciences, Inc. is betting on this trend with Vedanta Biosciences, a platform that defined bacterial consortia therapeutics rationally designed to m...
Second Genome, Inc. Unveils Strain-Level Therapeutics Engine for Pharmaceutical & Drug Development
As the microbiome analysis & therapeutics market heats up — analysts project it will reach $1.6 billion by 2028 — Second Genome, Inc. has made its move. The company's platform, Second Genome, microbiome-derived small molecule and protein therapeutics discovered through functional genomics. Second Ge...
How Unlearn.AI, Inc. Is Reducing Clinical Research & CROs Trial Failure Rates with Digital Twins
Unlearn.AI, Inc. has entered the digital twins & in silico trials arena with Unlearn.AI, a platform that ai-generated digital twins replacing placebo arms to accelerate clinical trials with fewer patients. The move positions the company in a market projected to reach $1.8 billion by 2028, where in s...
Twin Health, Inc. Launches In Silico Trial Platform for Healthcare & Hospital Systems
For healthcare & hospital systems operators looking to modernize their digital twins & in silico trials capabilities, Twin Health, Inc. is pitching a compelling proposition. Twin Health whole body digital twin platform achieving drug-free remission of type 2 diabetes and metabolic disease, addressin...
How Dassault Systèmes SE Is Reducing Pharmaceutical & Drug Development Trial Failure Rates with Digital Twins
Dassault Systèmes SE has entered the digital twins & in silico trials arena with Dassault Systèmes SIMULIA (Living Heart Project), a platform that physics-based virtual human simulation enabling in silico clinical trials for cardiovascular devices and drugs. The move positions the company in a marke...
InSilicoTrials Technologies S.p.A. Introduces Virtual Patient Modeling for Clinical Research & CROs
For clinical research & cros operators looking to modernize their digital twins & in silico trials capabilities, InSilicoTrials Technologies S.p.A. is pitching a compelling proposition. InSilicoTrials cloud-based platform aggregating computational models for regulatory-grade in silico clinical trial...
electroCore, Inc. Deploys Brain-Computer Interface Technology Across Healthcare & Hospital Systems
As the bioelectronic medicine & neurostimulation market heats up — analysts project it will reach $1.4 billion by 2028 — electroCore, Inc. has made its move. The company's platform, gammaCore (electroCore), non-invasive vagus nerve stimulator delivering fda-cleared therapy for migraine, cluster head...
How SetPoint Medical Corporation Is Advancing Healthcare & Hospital Systems Neurotech with Adaptive AI
The bioelectronic medicine & neurostimulation segment is undergoing rapid transformation as enterprises embrace a new reality: closed-loop neural interfaces are enabling adaptive therapy protocols. SetPoint Medical Corporation is positioning itself at the center of this shift with SetPoint Medical, ...
How Nalu Medical, Inc. Is Advancing Healthcare & Hospital Systems Neurotech with Adaptive AI
As the bioelectronic medicine & neurostimulation market heats up — analysts project it will reach $1.4 billion by 2028 — Nalu Medical, Inc. has made its move. The company's platform, Nalu Medical Micro-IPG, ultra-miniature rechargeable neurostimulator enabling precise spinal cord and peripheral nerv...
Saluda Medical Pty Ltd Unveils AI-Powered Neurostimulation Platform for Healthcare & Hospital Systems
Saluda Medical Pty Ltd has entered the bioelectronic medicine & neurostimulation arena with Saluda Medical Evoke System, a platform that closed-loop spinal cord stimulation that automatically adapts therapy in real time. The move positions the company in a market projected to reach $1.4 billion by 2...
How Axonics, Inc. Is Advancing Healthcare & Hospital Systems Neurotech with Adaptive AI
As the bioelectronic medicine & neurostimulation market heats up — analysts project it will reach $1.4 billion by 2028 — Axonics, Inc. has made its move. The company's platform, Axonics Sacral Neuromodulation System, long-lasting sacral neuromodulation that restores bladder and bowel control. Axonic...
How Altos Labs, Inc. Is Reducing Biotechnology Startups Trial Failure Rates with Digital Twins
With in silico trials have reduced Phase I costs by 15-30%, the case for AI-powered longevity & anti-aging technology has never been stronger. Altos Labs, Inc. is betting on this trend with Altos Labs Research Platform, a platform that cellular rejuvenation programming to restore cell health and rev...
Retro Biosciences, Inc. Unveils Digital Twin Technology for Biotechnology Startups Clinical Development
The longevity & anti-aging technology segment is undergoing rapid transformation as enterprises embrace a new reality: organ-level digital twins are enabling personalized dosing simulations. Retro Biosciences, Inc. is positioning itself at the center of this shift with Retro Biosciences Platform, wh...
Calico Life Sciences LLC Introduces Virtual Patient Modeling for Pharmaceutical & Drug Development
For pharmaceutical & drug development operators looking to modernize their longevity & anti-aging technology capabilities, Calico Life Sciences LLC is pitching a compelling proposition. Calico Life Sciences Platform alphabet-backed research lab harnessing biology to understand the biology of aging, ...
How Unity Biotechnology, Inc. Is Reducing Pharmaceutical & Drug Development Trial Failure Rates with Digital Twins
As the longevity & anti-aging technology market heats up — analysts project it will reach $1.8 billion by 2028 — Unity Biotechnology, Inc. has made its move. The company's platform, Unity Biotechnology Senolytic Platform, senolytic medicines that selectively eliminate senescent cells to treat aging-...
Loyal, Inc. Launches In Silico Trial Platform for Biotechnology Startups
For biotechnology startups operators looking to modernize their longevity & anti-aging technology capabilities, Loyal, Inc. is pitching a compelling proposition. Loyal for Dogs Longevity Platform developing the first drugs to extend healthy lifespan in dogs — and pioneer human longevity, addressing ...
Siemens Healthineers AG Introduces Virtual Patient Modeling for Healthcare & Hospital Systems
The digital twins & in silico trials segment is undergoing rapid transformation as enterprises embrace a new reality: organ-level digital twins are enabling personalized dosing simulations. Siemens Healthineers AG is positioning itself at the center of this shift with Siemens Healthineers Digital Tw...
Inside Ginkgo Bioworks Holdings, Inc.'s Push to Democratize Biomanufacturing & Bioprocess Synthetic Biology
Ginkgo Bioworks Holdings, Inc. has positioned itself as a significant player in synthetic biology platforms, a segment where enterprises are demanding solutions that deliver measurable results. The organism engineering platform making biology easier to engineer. Ginkgo Bioworks operates the world's ...
How Insilico Medicine, Inc. Is Accelerating Pharmaceutical & Drug Development Drug Discovery with Machine Learning
With 65% of top-20 pharma companies now use AI in early-stage discovery, the case for AI-powered ai drug discovery has never been stronger. Insilico Medicine, Inc. is betting on this trend with Insilico Medicine, a platform that end-to-end ai platform for target discovery, molecule generation, and c...
Google DeepMind Rolls Out AI Structure Prediction for Academic Research & Universities Biologics
The protein structure & design segment is undergoing rapid transformation as enterprises embrace a new reality: generative AI is designing novel proteins with desired functional properties. Google DeepMind is positioning itself at the center of this shift with AlphaFold, which ai system predicting 3...
How Schrödinger, Inc. Is Advancing Pharmaceutical & Drug Development Computational Drug Design
Schrödinger, Inc. has entered the computational chemistry arena with Schrödinger, a platform that physics-based molecular simulation platform accelerating drug discovery and materials design. The move positions the company in a market projected to reach $5.1 billion by 2028, where physics-based simu...
Recursion Pharmaceuticals, Inc. Launches AI-Powered Drug Discovery Platform for Pharmaceutical & Drug Development
Recursion Pharmaceuticals, Inc. has positioned itself as a significant player in ai drug discovery, a segment where enterprises are demanding solutions that deliver measurable results. Decoding biology to industrialize drug discovery with AI and automation. Recursion Pharmaceuticals operates one of ...
Cellarity Unveils AI Platform for Cell-Targeting Drug Discovery
Cellarity, a Flagship Pioneering company, has launched an innovative AI platform designed to discover and develop cell-targeted medicines. This platform leverages proprietary AI models to analyze comp